Sen. Julie A. Morrison

Filed: 3/17/2023

 

 


 

 


 
10300SB1987sam001LRB103 25792 RLC 58970 a

1
AMENDMENT TO SENATE BILL 1987

2    AMENDMENT NO. ______. Amend Senate Bill 1987 by replacing
3everything after the enacting clause with the following:
 
4    "Section 5. The Illinois Controlled Substances Act is
5amended by changing Section 204 as follows:
 
6    (720 ILCS 570/204)  (from Ch. 56 1/2, par. 1204)
7    Sec. 204. (a) The controlled substances listed in this
8Section are included in Schedule I.
9    (b) Unless specifically excepted or unless listed in
10another schedule, any of the following opiates, including
11their isomers, esters, ethers, salts, and salts of isomers,
12esters, and ethers, whenever the existence of such isomers,
13esters, ethers and salts is possible within the specific
14chemical designation:
15        (1) Acetylmethadol;
16        (1.1) Acetyl-alpha-methylfentanyl

 

 

10300SB1987sam001- 2 -LRB103 25792 RLC 58970 a

1    (N-[1-(1-methyl-2-phenethyl)-
2    4-piperidinyl]-N-phenylacetamide);
3        (2) Allylprodine;
4        (3) Alphacetylmethadol, except
5    levo-alphacetylmethadol (also known as levo-alpha-
6    acetylmethadol, levomethadyl acetate, or LAAM);
7        (4) Alphameprodine;
8        (5) Alphamethadol;
9        (6) Alpha-methylfentanyl
10    (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
11    propionanilide;  1-(1-methyl-2-phenylethyl)-4-(N-
12    propanilido) piperidine;
13        (6.1) Alpha-methylthiofentanyl
14    (N-[1-methyl-2-(2-thienyl)ethyl-
15    4-piperidinyl]-N-phenylpropanamide);
16        (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
17        (7.1) PEPAP
18    (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
19        (8) Benzethidine;
20        (9) Betacetylmethadol;
21        (9.1) Beta-hydroxyfentanyl
22    (N-[1-(2-hydroxy-2-phenethyl)-
23    4-piperidinyl]-N-phenylpropanamide);
24        (10) Betameprodine;
25        (11) Betamethadol;
26        (12) Betaprodine;

 

 

10300SB1987sam001- 3 -LRB103 25792 RLC 58970 a

1        (13) Clonitazene;
2        (14) Dextromoramide;
3        (15) Diampromide;
4        (16) Diethylthiambutene;
5        (17) Difenoxin;
6        (18) Dimenoxadol;
7        (19) Dimepheptanol;
8        (20) Dimethylthiambutene;
9        (21) Dioxaphetylbutyrate;
10        (22) Dipipanone;
11        (23) Ethylmethylthiambutene;
12        (24) Etonitazene;
13        (25) Etoxeridine;
14        (26) Furethidine;
15        (27) Hydroxpethidine;
16        (28) Ketobemidone;
17        (29) Levomoramide;
18        (30) Levophenacylmorphan;
19        (31) 3-Methylfentanyl
20    (N-[3-methyl-1-(2-phenylethyl)-
21    4-piperidyl]-N-phenylpropanamide);
22        (31.1) 3-Methylthiofentanyl
23    (N-[(3-methyl-1-(2-thienyl)ethyl-
24    4-piperidinyl]-N-phenylpropanamide);
25        (32) Morpheridine;
26        (33) Noracymethadol;

 

 

10300SB1987sam001- 4 -LRB103 25792 RLC 58970 a

1        (34) Norlevorphanol;
2        (35) Normethadone;
3        (36) Norpipanone;
4        (36.1) Para-fluorofentanyl
5    (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
6    4-piperidinyl]propanamide);
7        (37) Phenadoxone;
8        (38) Phenampromide;
9        (39) Phenomorphan;
10        (40) Phenoperidine;
11        (41) Piritramide;
12        (42) Proheptazine;
13        (43) Properidine;
14        (44) Propiram;
15        (45) Racemoramide;
16        (45.1) Thiofentanyl
17    (N-phenyl-N-[1-(2-thienyl)ethyl-
18    4-piperidinyl]-propanamide);
19        (46) Tilidine;
20        (47) Trimeperidine;
21        (48) Beta-hydroxy-3-methylfentanyl (other name:
22    N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
23    N-phenylpropanamide);
24        (49) Furanyl fentanyl (FU-F);
25        (50) Butyryl fentanyl;
26        (51) Valeryl fentanyl;

 

 

10300SB1987sam001- 5 -LRB103 25792 RLC 58970 a

1        (52) Acetyl fentanyl;
2        (53) Beta-hydroxy-thiofentanyl;
3        (54) 3,4-dichloro-N-[2-
4    (dimethylamino)cyclohexyl]-N-
5    methylbenzamide (U-47700); 
6        (55) 4-chloro-N-[1-[2-
7    (4-nitrophenyl)ethyl]-2-piperidinylidene]-
8    benzenesulfonamide (W-18); 
9        (56) 4-chloro-N-[1-(2-phenylethyl)
10    -2-piperidinylidene]-benzenesulfonamide (W-15); 
11        (57) acrylfentanyl (acryloylfentanyl). 
12    (c) Unless specifically excepted or unless listed in
13another schedule, any of the following opium derivatives, its
14salts, isomers and salts of isomers, whenever the existence of
15such salts, isomers and salts of isomers is possible within
16the specific chemical designation:
17        (1) Acetorphine;
18        (2) Acetyldihydrocodeine;
19        (3) Benzylmorphine;
20        (4) Codeine methylbromide;
21        (5) Codeine-N-Oxide;
22        (6) Cyprenorphine;
23        (7) Desomorphine;
24        (8) Diacetyldihydromorphine (Dihydroheroin);
25        (9) Dihydromorphine;
26        (10) Drotebanol;

 

 

10300SB1987sam001- 6 -LRB103 25792 RLC 58970 a

1        (11) Etorphine (except hydrochloride salt);
2        (12) Heroin;
3        (13) Hydromorphinol;
4        (14) Methyldesorphine;
5        (15) Methyldihydromorphine;
6        (16) Morphine methylbromide;
7        (17) Morphine methylsulfonate;
8        (18) Morphine-N-Oxide;
9        (19) Myrophine;
10        (20) Nicocodeine;
11        (21) Nicomorphine;
12        (22) Normorphine;
13        (23) Pholcodine;
14        (24) Thebacon.
15    (d) Unless specifically excepted or unless listed in
16another schedule, any material, compound, mixture, or
17preparation which contains any quantity of the following
18hallucinogenic substances, or which contains any of its salts,
19isomers and salts of isomers, whenever the existence of such
20salts, isomers, and salts of isomers is possible within the
21specific chemical designation (for the purposes of this
22paragraph only, the term "isomer" includes the optical,
23position and geometric isomers):
24        (1) 3,4-methylenedioxyamphetamine
25    (alpha-methyl,3,4-methylenedioxyphenethylamine,
26    methylenedioxyamphetamine, MDA);

 

 

10300SB1987sam001- 7 -LRB103 25792 RLC 58970 a

1        (1.1) Alpha-ethyltryptamine
2    (some trade or other names: etryptamine;
3    MONASE; alpha-ethyl-1H-indole-3-ethanamine;
4    3-(2-aminobutyl)indole; a-ET; and AET);
5        (2) 3,4-methylenedioxymethamphetamine (MDMA);
6        (2.1) 3,4-methylenedioxy-N-ethylamphetamine
7    (also known as: N-ethyl-alpha-methyl-
8    3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
9    and MDEA);
10        (2.2) N-Benzylpiperazine (BZP);
11        (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
12        (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
13        (4) 3,4,5-trimethoxyamphetamine (TMA);
14        (5) (Blank);
15        (6) Diethyltryptamine (DET);
16        (7) Dimethyltryptamine (DMT);
17        (7.1) 5-Methoxy-diallyltryptamine;
18        (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
19        (9) Ibogaine  (some trade and other names:
20    7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
21    6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
22    indole; Tabernanthe iboga);
23        (10) Lysergic acid diethylamide;
24        (10.1) Salvinorin A;
25        (10.5) Salvia divinorum (meaning all parts of the
26    plant presently classified botanically as Salvia

 

 

10300SB1987sam001- 8 -LRB103 25792 RLC 58970 a

1    divinorum, whether growing or not, the seeds thereof, any
2    extract from any part of that plant, and every compound,
3    manufacture, salts, isomers, and salts of isomers whenever
4    the existence of such salts, isomers, and salts of isomers
5    is possible within the specific chemical designation,
6    derivative, mixture, or preparation of that plant, its
7    seeds or extracts);
8        (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
9        (12) Peyote (meaning all parts of the plant presently
10    classified botanically as Lophophora williamsii Lemaire,
11    whether growing or not, the seeds thereof, any extract
12    from any part of that plant, and every compound,
13    manufacture, salts, derivative, mixture, or preparation of
14    that plant, its seeds or extracts);
15        (13) N-ethyl-3-piperidyl benzilate (JB 318);
16        (14) N-methyl-3-piperidyl benzilate;
17        (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
18    (also known as N-hydroxy-alpha-methyl-
19    3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
20        (15) Parahexyl; some trade or other names:
21    3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
22    dibenzo (b,d) pyran; Synhexyl;
23        (16) Psilocybin;
24        (17) Psilocyn;
25        (18) Alpha-methyltryptamine (AMT);
26        (19) 2,5-dimethoxyamphetamine

 

 

10300SB1987sam001- 9 -LRB103 25792 RLC 58970 a

1    (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
2        (20) 4-bromo-2,5-dimethoxyamphetamine
3    (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
4    4-bromo-2,5-DMA);
5        (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
6    Some trade or other names: 2-(4-bromo-
7    2,5-dimethoxyphenyl)-1-aminoethane;
8    alpha-desmethyl DOB, 2CB, Nexus;
9        (21) 4-methoxyamphetamine
10    (4-methoxy-alpha-methylphenethylamine;
11    paramethoxyamphetamine; PMA);
12        (22) (Blank);
13        (23) Ethylamine analog of phencyclidine.
14    Some trade or other names:
15    N-ethyl-1-phenylcyclohexylamine,
16    (1-phenylcyclohexyl) ethylamine,
17    N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
18        (24) Pyrrolidine analog of phencyclidine. Some trade
19    or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
20    PHP;
21        (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
22        (26) 2,5-dimethoxy-4-ethylamphetamine
23    (another name: DOET);
24        (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
25    (another name: TCPy);
26        (28) (Blank);

 

 

10300SB1987sam001- 10 -LRB103 25792 RLC 58970 a

1        (29) Thiophene analog of phencyclidine (some trade
2    or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
3    2-thienyl analog of phencyclidine; TPCP; TCP);
4        (29.1) Benzothiophene analog of phencyclidine. Some
5    trade or other names: BTCP or benocyclidine;
6        (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
7        (30) Bufotenine (some trade or other names:
8    3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
9    3-(2-dimethylaminoethyl)-5-indolol;
10    5-hydroxy-N,N-dimethyltryptamine;
11    N,N-dimethylserotonin; mappine);
12        (31) (Blank);  
13        (32) (Blank);  
14        (33) (Blank);  
15        (34) (Blank); 
16        (34.5) (Blank);  
17        (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
18    (2-methyloctan-2-yl)-6a,7, 
19    10,10a-tetrahydrobenzo[c]chromen-1-ol
20    Some trade or other names: HU-210; 
21        (35.5)  (6aS,10aS)-9-(hydroxymethyl)-6,6- 
22    dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
23    tetrahydrobenzo[c]chromen-1-ol, its isomers,  
24    salts, and salts of isomers; Some trade or other  
25    names: HU-210, Dexanabinol; 
26        (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-

 

 

10300SB1987sam001- 11 -LRB103 25792 RLC 58970 a

1    6,6-dimethyl-3-(2-methyloctan-2-yl)- 
2    6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
3    Some trade or other names: HU-211;
4        (37) (Blank);
5        (38) (Blank);
6        (39) (Blank);
7        (40) (Blank);
8        (41) (Blank);
9        (42) Any compound structurally derived from
10    3-(1-naphthoyl)indole or
11    1H-indol-3-yl-(1-naphthyl)methane by substitution at the
12    nitrogen atom of the indole ring by alkyl, haloalkyl,
13    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
14    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
15    2-(4-morpholinyl)ethyl whether or not further substituted
16    in the indole ring to any extent, whether or not
17    substituted in the naphthyl ring to any extent. Examples
18    of this structural class include, but are not limited to,
19    JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
20        (43) Any compound structurally derived from
21    3-(1-naphthoyl)pyrrole by substitution at the nitrogen
22    atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
23    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
24    halide, 1-(N-methyl-2-piperidinyl)methyl, or
25    2-(4-morpholinyl)ethyl, whether or not further substituted
26    in the pyrrole ring to any extent, whether or not

 

 

10300SB1987sam001- 12 -LRB103 25792 RLC 58970 a

1    substituted in the naphthyl ring to any extent. Examples
2    of this structural class include, but are not limited to,
3    JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
4        (44) Any compound structurally derived from
5    1-(1-naphthylmethyl)indene by substitution at the
6    3-position of the indene ring by alkyl, haloalkyl,
7    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
8    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
9    2-(4-morpholinyl)ethyl whether or not further substituted
10    in the indene ring to any extent, whether or not
11    substituted in the naphthyl ring to any extent. Examples
12    of this structural class include, but are not limited to,
13    JWH-176;
14        (45) Any compound structurally derived from
15    3-phenylacetylindole by substitution at the nitrogen atom
16    of the indole ring with alkyl, haloalkyl, alkenyl,
17    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
18    halide, 1-(N-methyl-2-piperidinyl)methyl, or
19    2-(4-morpholinyl)ethyl, whether or not further substituted
20    in the indole ring to any extent, whether or not
21    substituted in the phenyl ring to any extent. Examples of
22    this structural class include, but are not limited to,
23    JWH-167, JWH-250, JWH-251, and RCS-8;
24        (46) Any compound structurally derived from
25    2-(3-hydroxycyclohexyl)phenol by substitution at the
26    5-position of the phenolic ring by alkyl, haloalkyl,

 

 

10300SB1987sam001- 13 -LRB103 25792 RLC 58970 a

1    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
2    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
3    2-(4-morpholinyl)ethyl, whether or not substituted in the
4    cyclohexyl ring to any extent. Examples of this structural
5    class include, but are not limited to, CP 47, 497 and its
6    C8 homologue (cannabicyclohexanol);
7        (46.1) Any compound structurally derived from
8    3-(benzoyl) indole with substitution at the nitrogen atom
9    of the indole ring by an alkyl, haloalkyl, alkenyl,
10    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
11    halide, 1-(N-methyl-2-piperidinyl)methyl, or
12    2-(4-morpholinyl)ethyl group whether or not further
13    substituted in the indole ring to any extent and whether
14    or not substituted in the phenyl ring to any extent.
15    Examples of this structural class include, but are not
16    limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
17    48,098), and RCS-4;
18        (47) (Blank);
19        (48) (Blank);
20        (49) (Blank);
21        (50) (Blank);
22        (51) (Blank);
23        (52) (Blank);
24        (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
25    Some trade or other names: 2C-T-7;
26        (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some

 

 

10300SB1987sam001- 14 -LRB103 25792 RLC 58970 a

1    trade or other names: 2C-E;
2        (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
3    trade or other names: 2C-D;
4        (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
5    trade or other names: 2C-C;
6        (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
7    or other names: 2C-I;
8        (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
9    trade or other names: 2C-T-2;
10        (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
11    Some trade or other names: 2C-T-4;
12        (53.7) 2,5-dimethoxyphenethylamine. Some trade or
13    other names: 2C-H;
14        (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
15    trade or other names: 2C-N;
16        (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
17    trade or other names: 2C-P;
18        (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
19    Some trade or other names: 2C-G;
20        (53.11) The N-(2-methoxybenzyl) derivative of any 2C
21    phenethylamine referred to in subparagraphs (20.1), (53),
22    (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
23    (53.8), (53.9), and (53.10) including, but not limited to,
24    25I-NBOMe and 25C-NBOMe;
25        (54) 5-Methoxy-N,N-diisopropyltryptamine;
26        (55) (Blank);

 

 

10300SB1987sam001- 15 -LRB103 25792 RLC 58970 a

1        (56) (Blank);
2        (57) (Blank);
3        (58) (Blank);
4        (59) 3-cyclopropoylindole with substitution at the
5    nitrogen atom of the indole ring by alkyl, haloalkyl,
6    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
7    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
8    2-(4-morpholinyl)ethyl, whether or not further substituted
9    on the indole ring to any extent, whether or not
10    substituted on the cyclopropyl ring to any extent:
11    including, but not limited to, XLR11, UR144, FUB-144;
12        (60) 3-adamantoylindole with substitution at the
13    nitrogen atom of the indole ring by alkyl, haloalkyl,
14    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
15    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
16    2-(4-morpholinyl)ethyl, whether or not further substituted
17    on the indole ring to any extent, whether or not
18    substituted on the adamantyl ring to any extent:
19    including, but not limited to, AB-001;
20        (61) N-(adamantyl)-indole-3-carboxamide with
21    substitution at the nitrogen atom of the indole ring by
22    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
23    cycloalkylethyl, aryl halide, alkyl aryl halide,
24    1-(N-methyl-2-piperidinyl)methyl, or
25    2-(4-morpholinyl)ethyl, whether or not further substituted
26    on the indole ring to any extent, whether or not

 

 

10300SB1987sam001- 16 -LRB103 25792 RLC 58970 a

1    substituted on the adamantyl ring to any extent:
2    including, but not limited to, APICA/2NE-1, STS-135;
3        (62) N-(adamantyl)-indazole-3-carboxamide with
4    substitution at a nitrogen atom of the indazole ring by
5    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
6    cycloalkylethyl, aryl halide, alkyl aryl halide,
7    1-(N-methyl-2-piperidinyl)methyl, or
8    2-(4-morpholinyl)ethyl, whether or not further substituted
9    on the indazole ring to any extent, whether or not
10    substituted on the adamantyl ring to any extent:
11    including, but not limited to, AKB48, 5F-AKB48;
12        (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
13    with substitution at the nitrogen atom of the indole ring
14    by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
15    cycloalkylethyl, aryl halide, alkyl aryl halide,
16    1-(N-methyl-2-piperidinyl)methyl, or
17    2-(4-morpholinyl)ethyl, whether or not further substituted
18    on the indole ring to any extent, whether or not
19    substituted on the quinoline ring to any extent:
20    including, but not limited to, PB22, 5F-PB22, FUB-PB-22;
21        (64) 3-(1-naphthoyl)indazole with substitution at the
22    nitrogen atom of the indazole ring by alkyl, haloalkyl,
23    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
24    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
25    2-(4-morpholinyl)ethyl, whether or not further substituted
26    on the indazole ring to any extent, whether or not

 

 

10300SB1987sam001- 17 -LRB103 25792 RLC 58970 a

1    substituted on the naphthyl ring to any extent: including,
2    but not limited to, THJ-018, THJ-2201;
3        (65) 2-(1-naphthoyl)benzimidazole with substitution
4    at the nitrogen atom of the benzimidazole ring by alkyl,
5    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
6    aryl halide, alkyl aryl halide,
7    1-(N-methyl-2-piperidinyl)methyl, or
8    2-(4-morpholinyl)ethyl, whether or not further substituted
9    on the benzimidazole ring to any extent, whether or not
10    substituted on the naphthyl ring to any extent: including,
11    but not limited to, FUBIMINA;
12        (66)
13    N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
14    3-carboxamide with substitution on the nitrogen atom of
15    the indazole ring by alkyl, haloalkyl, alkenyl,
16    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
17    halide, 1-(N-methyl-2-piperidinyl)methyl, or
18    2-(4-morpholinyl)ethyl, whether or not further substituted
19    on the indazole ring to any extent: including, but not
20    limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
21        (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
22    indazole-3-carboxamide with substitution on the nitrogen
23    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
24    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
25    halide, 1-(N-methyl-2-piperidinyl)methyl, or
26    2-(4-morpholinyl)ethyl, whether or not further substituted

 

 

10300SB1987sam001- 18 -LRB103 25792 RLC 58970 a

1    on the indazole ring to any extent: including, but not
2    limited to, ADB-PINACA, ADB-FUBINACA;
3        (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
4    indole-3-carboxamide with substitution on the nitrogen
5    atom of the indole ring by alkyl, haloalkyl, alkenyl,
6    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
7    halide, 1-(N-methyl-2-piperidinyl)methyl, or
8    2-(4-morpholinyl)ethyl, whether or not further substituted
9    on the indole ring to any extent: including, but not
10    limited to, ADBICA, 5F-ADBICA;
11        (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
12    3-carboxamide with substitution on the nitrogen atom of
13    the indole ring by alkyl, haloalkyl, alkenyl,
14    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
15    halide, 1-(N-methyl-2-piperidinyl)methyl, or
16    2-(4-morpholinyl)ethyl, whether or not further substituted
17    on the indole ring to any extent: including, but not
18    limited to, ABICA, 5F-ABICA;
19        (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
20    methylbutanoate with substitution on the nitrogen atom of
21    the indazole ring by alkyl, haloalkyl, alkenyl,
22    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
23    halide, 1-(N-methyl-2-piperidinyl)methyl, or
24    2-(4-morpholinyl)ethyl, whether or not further substituted
25    on the indazole ring to any extent: including, but not
26    limited to, AMB, 5F-AMB;

 

 

10300SB1987sam001- 19 -LRB103 25792 RLC 58970 a

1        (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
2    dimethylbutanoate with substitution on the nitrogen atom
3    of the indazole ring by alkyl, haloalkyl, alkenyl,
4    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
5    halide, 1-(N-methyl-2-piperidinyl)methyl, or
6    2-(4-morpholinyl)ethyl, whether or not further substituted
7    on the indazole ring to any extent: including, but not
8    limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
9        (72) Methyl 2-(1H-indole-3-carboxamido)-3-
10    methylbutanoate with substitution on the nitrogen atom of
11    the indole ring by alkyl, haloalkyl, alkenyl,
12    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
13    halide, 1-(N-methyl-2-piperidinyl)methyl, or
14    2-(4-morpholinyl)ethyl, whether or not further substituted
15    on the indazole ring to any extent: including, but not
16    limited to, MMB018, MMB2201, and AMB-CHMICA;
17        (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
18    dimethylbutanoate with substitution on the nitrogen atom
19    of the indole ring by alkyl, haloalkyl, alkenyl,
20    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
21    halide, 1-(N-methyl-2-piperidinyl)methyl, or
22    2-(4-morpholinyl)ethyl, whether or not further substituted
23    on the indazole ring to any extent: including, but not
24    limited to, MDMB-CHMICA;
25        (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
26    indazole-3-carboxamide with substitution on the nitrogen

 

 

10300SB1987sam001- 20 -LRB103 25792 RLC 58970 a

1    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
2    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
3    halide, 1-(N-methyl-2-piperidinyl)methyl, or
4    2-(4-morpholinyl)ethyl, whether or not further substituted
5    on the indazole ring to any     extent: including, but not
6    limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
7        (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
8    3-carboxamide with substitution on the nitrogen atom of
9    the indole ring by alkyl, haloalkyl, alkenyl,
10    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
11    halide, 1-(N-methyl-2-piperidinyl)methyl, or
12    2-(4-morpholinyl)ethyl, whether or not further substituted
13    on the indazole ring to any extent: including, but not
14    limited to, APP-PICA and 5-fluoro-APP-PICA;
15        (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
16    4-AcO-DMT;
17        (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
18    name 5-MeO-MIPT;
19        (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
20        (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
21        (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
22        (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
23    (4-HO-MiPT);
24        (82) Fluorophenylpiperazine;
25        (83) Methoxetamine;
26        (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-

 

 

10300SB1987sam001- 21 -LRB103 25792 RLC 58970 a

1    ethcathinone).
2    (e) Unless specifically excepted or unless listed in
3another schedule, any material, compound, mixture, or
4preparation which contains any quantity of the following
5substances having a depressant effect on the central nervous
6system, including its salts, isomers, and salts of isomers
7whenever the existence of such salts, isomers, and salts of
8isomers is possible within the specific chemical designation:
9        (1) mecloqualone;
10        (2) methaqualone; and
11        (3) gamma hydroxybutyric acid.
12    (f) Unless specifically excepted or unless listed in
13another schedule, any material, compound, mixture, or
14preparation which contains any quantity of the following
15substances having a stimulant effect on the central nervous
16system, including its salts, isomers, and salts of isomers:
17        (1) Fenethylline;
18        (2) N-ethylamphetamine;
19        (3) Aminorex (some other names:
20    2-amino-5-phenyl-2-oxazoline; aminoxaphen;
21    4-5-dihydro-5-phenyl-2-oxazolamine) and its
22    salts, optical isomers, and salts of optical isomers;
23        (4) Methcathinone (some other names:
24    2-methylamino-1-phenylpropan-1-one;
25    Ephedrone; 2-(methylamino)-propiophenone;
26    alpha-(methylamino)propiophenone; N-methylcathinone;

 

 

10300SB1987sam001- 22 -LRB103 25792 RLC 58970 a

1    methycathinone; Monomethylpropion; UR 1431) and its
2    salts, optical isomers, and salts of optical isomers;
3        (5) Cathinone (some trade or other names:
4    2-aminopropiophenone; alpha-aminopropiophenone;
5    2-amino-1-phenyl-propanone; norephedrone);
6        (6) N,N-dimethylamphetamine (also known as:
7    N,N-alpha-trimethyl-benzeneethanamine;
8    N,N-alpha-trimethylphenethylamine);
9        (7) (+ or -) cis-4-methylaminorex  ((+ or -) cis-
10    4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
11        (8) 3,4-Methylenedioxypyrovalerone (MDPV);
12        (9) Halogenated amphetamines and
13    methamphetamines - any compound derived from either
14    amphetamine or methamphetamine through the substitution
15    of a halogen on the phenyl ring, including, but not
16    limited to, 2-fluoroamphetamine, 3-
17    fluoroamphetamine and 4-fluoroamphetamine; 
18        (10) Aminopropylbenzofuran (APB):
19    including 4-(2-Aminopropyl) benzofuran, 5-
20    (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
21    benzofuran, and 7-(2-Aminopropyl) benzofuran; 
22        (11) Aminopropyldihydrobenzofuran (APDB):
23    including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
24    5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
25    6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
26    and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; 

 

 

10300SB1987sam001- 23 -LRB103 25792 RLC 58970 a

1        (12) Methylaminopropylbenzofuran
2    (MAPB): including 4-(2-methylaminopropyl)
3    benzofuran, 5-(2-methylaminopropyl)benzofuran,
4    6-(2-methylaminopropyl)benzofuran
5    and 7-(2-methylaminopropyl)benzofuran. 
6    (g) Temporary listing of substances subject to emergency
7scheduling. Any material, compound, mixture, or preparation
8that contains any quantity of the following substances:
9        (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
10    (benzylfentanyl), its optical isomers, isomers, salts, and
11    salts of isomers;
12        (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
13    phenylpropanamide (thenylfentanyl), its optical isomers,
14    salts, and salts of isomers.
15    (h) Synthetic cathinones. Unless specifically excepted,
16any chemical compound which is not approved by the United
17States Food and Drug Administration or, if approved, is not
18dispensed or possessed in accordance with State or federal
19law, not including bupropion, structurally derived from
202-aminopropan-1-one by substitution at the 1-position with
21either phenyl, naphthyl, or thiophene ring systems, whether or
22not the compound is further modified in one or more of the
23following ways:
24        (1) by substitution in the ring system to any extent
25    with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
26    halide substituents, whether or not further substituted in

 

 

10300SB1987sam001- 24 -LRB103 25792 RLC 58970 a

1    the ring system by one or more other univalent
2    substituents. Examples of this class include, but are not
3    limited to, 3,4-Methylenedioxycathinone (bk-MDA);
4        (2) by substitution at the 3-position with an acyclic
5    alkyl substituent. Examples of this class include, but are
6    not limited to, 2-methylamino-1-phenylbutan-1-one
7    (buphedrone); or
8        (3) by substitution at the 2-amino nitrogen atom with
9    alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
10    inclusion of the 2-amino nitrogen atom in a cyclic
11    structure. Examples of this class include, but are not
12    limited to, Dimethylcathinone, Ethcathinone, and
13    a-Pyrrolidinopropiophenone (a-PPP); or
14    Any other synthetic cathinone which is not approved by the
15United States Food and Drug Administration or, if approved, is
16not dispensed or possessed in accordance with State or federal
17law.
18    (i) Synthetic cannabinoids or piperazines. Any synthetic
19cannabinoid or piperazine which is not approved by the United
20States Food and Drug Administration or, if approved, which is
21not dispensed or possessed in accordance with State and
22federal law.
23    (j) Unless specifically excepted or listed in another
24schedule, any chemical compound which is not approved by the
25United States Food and Drug Administration or, if approved, is
26not dispensed or possessed in accordance with State or federal

 

 

10300SB1987sam001- 25 -LRB103 25792 RLC 58970 a

1law, and is derived from the following structural classes and
2their salts:
3        (1) Benzodiazepine class: A fused 1,4-diazepine and
4    benzene ring structure with a phenyl connected to the
5    1,4-diazepine ring, with any substitution(s) or
6    replacement(s) on the 1,4-diazepine or benzene ring, any
7    substitution(s) on the phenyl ring, or any combination
8    thereof. Examples of this class include but are not
9    limited to: Clonazolam, Flualprazolam; or
10        (2) Thienodiazepine class: A fused 1,4-diazepine and
11    thiophene ring structure with a phenyl connected to the
12    1,4-diazepine ring, with any substitution(s) or
13    replacement(s) on the 1,4-diazepine or thiophene ring, any
14    substitution(s) on the phenyl ring, or any combination
15    thereof. Examples of this class include but are not
16    limited to: Etizolam.
17(Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
18100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff.
198-14-18.)".